Investor alerts, case updates, and legal insights from the attorneys at Bronstein, Gewirtz & Grossman, LLC.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Gildan did not have adequate internal controls; (2) Gildan used channel stuffing to create an appearance of revenue; and (3) As a result, Defendants’…
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Triller’s control over and consolidation of Bare Knuckle Fighting Championship (“BKFC”) was tenuous, overstated, and/or non-existent; (2) Triller was unable…
On October 9, 2026, the Centers for Medicare & Medicaid Services (CMS) released its 2027 Medicare Advantage Star Ratings, revealing that Alignment Healthcare, Inc.’s largest California HMO contract, covering approximately 75% of its health-plan members, had been downgraded from 4.0 to 3.5 stars…
On October 12, 2026, Yiren announced Ning Tang, the Company's Executive Chairman and Chief Executive Officer, had been subject to criminal compulsory measures in connection with an investigation involving certain affiliates of the Company's controlling shareholder. Following this news, Yiren's…
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and financial prospects. Specifically, the complaint alleges that Defendants made false and/or misleading statements and/or failed to…
On October 13, 2026, the U.S. Department of the Treasury announced more than $1.21 billion in penalties against Bank of America for violations of federal anti-money laundering and sanctions laws. According to regulators, Bank of America failed to properly monitor trillions of dollars in…
On October 6, 2026, ArriVent BioPharma, Inc. announced that its global Phase 3 FURVENT trial evaluating firmonertinib in previously untreated patients with EGFR exon 20 insertion-mutated non-small-cell lung cancer failed to meet its primary endpoint of progression-free survival. Previously, the…
Be the first to know when BG&G files a new class action or announces a settlement deadline. No spam — only case-relevant alerts.
By subscribing you agree to our Privacy Policy. Unsubscribe anytime.